There is great concern about the impact of COVID-19 among the nearly 40 million people living with HIV (PLWH) worldwide. In this review, we surveyed current literature and found no evidence of higher prevalence of COVID-19 among PLWH but equivocal data on increased mortality and worse clinical outcomes. Having HIV does not confer protection against severe manifestations of COVID-19. Several studies looking at antiretroviral drugs against HIV to treat SARS-CoV-2 have shown no mortality benefit. Thus, there is no indication to change antiretroviral therapy (ART) regimens among virologically suppressed PLWH to prevent COVID-19. HIV care delivery has been adversely impacted in several countries during this pandemic but has created an opportunity for accelerating effective strategies like multi-month ART. Decentralizing HIV care in low-resource settings and incorporating telemedicine in high-resource settings will be critical in mitigating shocks to healthcare systems in the future.

人们对 COVID-19 对全球近 4000 万艾滋病毒感染者 (PLWH) 的影响非常担忧。在这篇综述中，我们调查了当前的文献，没有发现 PLWH 中 COVID-19 患病率较高的证据，但关于死亡率增加和临床结果恶化的数据模棱两可。感染 HIV 并不能提供针对 COVID-19 严重表现的保护。几项针对 HIV 的抗逆转录病毒药物治疗 SARS-CoV-2 的研究表明，并没有降低死亡率。因此，没有迹象表明需要改变病毒学抑制的 PLWH 的抗逆转录病毒治疗 (ART) 方案来预防 COVID-19。在这次大流行期间，一些国家的艾滋病毒护理服务受到了不利影响，但为加速实施多月抗逆转录病毒疗法等有效战略创造了机会。在资源匮乏的环境中分散艾滋病毒护理并在资源丰富的环境中纳入远程医疗对于减轻未来对医疗保健系统的冲击至关重要。